HGH (somatropin, research reference) — Literature-Reported Ranges & Study Protocols

Read this first

Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.

Compound at a glance

Class: Recombinant 191-amino-acid human growth hormone
Reported half-life: Approximately 3–5 hours subcutaneously
Routes used in the literature: Subcutaneous in essentially all clinical literature
Also written as: —

What the published studies reported

Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.

Adult GH deficiency replacement studies

Reported quantity: 0.15–0.3 mg per day initially, titrated to IGF-1 within reference range
Frequency: Once daily, usually evening
Study duration: 6–24 months in the published trials

Titration is to a measured IGF-1 value, not to a fixed quantity — this is the defining feature of the protocol.

Paediatric growth-disorder studies

Reported quantity: 0.025–0.05 mg/kg/day
Frequency: Once daily
Study duration: Years, to final height

Per-kilogram figures here are for a growing population and do not transfer to adults.

Body-composition research in adults

Reported quantity: Commonly 1–3 IU/day (roughly 0.33–1 mg/day)
Frequency: Once daily
Study duration: 12–26 weeks

1 mg is approximately 3 IU for modern recombinant preparations.

Dosage chart

These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.

HGH (191aa) · 10IU Vial

HGH 191AA is dosed at 200 mcg–900 mcg daily via subcutaneous injection in educational protocols. A 10IU vial reconstituted with bacteriostatic water yields about 1.11 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~1.11 mg/mL concentration (~1111 mcg/mL).
Typical daily range: 150–500 mcg (conservative replacement protocols) to 1000–2000 mcg (advanced metabolic studies).
Easy measuring: At 1.11 mg/mL, 1 unit = 0.01 mL ≈ 11.1 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Standard / Gradual Titration (3 mL = ~1.11 mg/mL)

Week	Daily Dose (mcg)	Units (per injection) (mL)
Week 1	200 mcg	18 units (0.18 mL)
Week 2	300 mcg	27 units (0.27 mL)
Week 3	400 mcg	36 units (0.36 mL)
Week 4	500 mcg	45 units (0.45 mL)
Week 5	600 mcg	54 units (0.54 mL)
Week 6	700 mcg	63 units (0.63 mL)
Week 7	800 mcg	72 units (0.72 mL)
Week 8	900 mcg	81 units (0.81 mL)

Source chart on peptidedosages.com

Reconstitution maths

Supplied in IU-labelled vials — commonly 10 IU (≈3.33 mg). 10 IU reconstituted with 1 mL gives 10 IU/mL, so 10 units on a 100-unit insulin syringe draws 1 IU.

Open the reconstitution calculator

How to read these figures

IU and mg are both in use and confusing them by a factor of three is the most common error in this field.
Glucose intolerance, fluid retention and carpal-tunnel symptoms are dose-related findings across the clinical literature.
It is a controlled or prescription-only substance in most jurisdictions and banned in sport.

Sources and citations

These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.

[1]
Growth Hormone (GH) Replacement Therapy in Adult-Onset GH Deficiency: Effects on Body Composition in Men and Women in a Double-Blind, Randomized, Placebo-Controlled Trial
Hoffman AR, Kuntze JE, Baptista J, et al. · Journal of Clinical Endocrinology & Metabolism · 2004 · PMID 15126520
Adults with GH deficiency received individually titrated recombinant human growth hormone (somatropin) injections over months to evaluate effects on body composition compared with placebo.
View the record
[2]
The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency
Cuneo RC, Salomon F, Wiles CM, et al. · New England Journal of Medicine · 1989 · PMID 2687691
In a six-month double-blind, placebo-controlled trial, 24 adults with GH deficiency received recombinant human growth hormone injections to assess body composition and metabolic changes.
View the record
[3]
Efficacy and safety of growth hormone (GH) in the treatment of adult Japanese patients with GH deficiency: a randomised, placebo-controlled study
Chihara K, Kato Y, Kohno H, et al. · Growth Hormone & IGF Research · 2006 · PMID 16702006
Adult Japanese patients with GH deficiency received randomized, weight-based somatropin doses in a placebo-controlled trial evaluating efficacy and safety.
View the record

Search the databases yourself

Read the HGH (somatropin, research reference) research brief

Other growth hormone compounds

AOD-9604hGH fragment 176-191 CJC-1295 (no DAC)Tetra-substituted GHRH (1-29) analogue CJC-1295 (no DAC) + IpamorelinGHRH analogue + selective ghrelin-receptor agonist blend CJC-1295 with DACGHRH analogue with albumin-binding drug affinity complex

All research protocols

Continue your research

Three steps most readers take from here

1 · Read the background
Mechanism, half-life and what the published HGH (somatropin, research reference) literature actually shows.
HGH (somatropin, research reference) research brief
2 · Plan the bench work
Work out reconstitution volumes and concentrations before ordering anything, so you buy the vial size your protocol actually needs.
Reconstitution calculator
3 · Check the paperwork
Only use material released with a lot-matched third-party certificate of analysis. Suppliers we have checked publish theirs openly.
HGH (somatropin, research reference) reference page How we verify suppliers

We are an independent publication: we sell nothing, hold no stock and take no payment. Outbound supplier links are marked nofollow/sponsored. Compounds discussed are laboratory research reagents, not medicines.

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.